CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Enteric hyperoxaluria: role of microbiota and antibiotics.

The renin–angiotensin system in the arcuate nucleus controls resting metabolic rate

Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition

Change in albuminuria as a surrogate endpoint.

Urgent-start peritoneal dialysis: is it ready for prime time?

Protective association between JC polyoma viruria and kidney disease

The kidney transcriptome, from single cells to whole organs and back

Bone and heart health in chronic kidney disease: role of dentin matrix protein 1

Citrate therapy for calcium phosphate stones

The use of antibiotics and risk of kidney stones.

Fluid management and bioimpedance study in peritoneal dialysis

Assessing the health of the nephron in acute kidney injury: biomarkers of kidney function and injury.

Hypoxia, hypoxia-inducible transcription factors and oxygen-sensing prolyl hydroxylases in bone development and homeostasis.

Skin autofluorescence: an emerging biomarker in persons with kidney disease.

Targeting angiotensinogen with RNA-based therapeutics.

Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Growth hormone and chronic kidney disease

Advances in management of chronic metabolic acidosis in chronic kidney disease.

When are you too old to get a kidney transplants?

Genes and environment in chronic kidney disease hotspots

Using race in the estimation of glomerular filtration rates: time for a reversal?

Revisiting therapeutic options for calciphylaxis.

Immunohistochemistry for aldosterone synthase CYP11B2 and matrix-assisted laser desorption ionization imaging mass spectrometry for in-situ aldosterone detection

Renal sympathetic denervation for treatment of hypertension: where are we now in 2019?

The emerging role of activins in renal disease.

Bariatric surgery as a renoprotective intervention.

Fibroblast growth factor 23 and phosphate homeostasis.

Phosphate, the forgotten mineral in hypertension.

Hyperphosphataemia in 2019: have we made progress?

Updates on medical management of hyperkalemia.

Cullin-Ring ubiquitin ligases in kidney health and disease.

Pre, peri and posttransplant diabetes mellitus

Updates in the management of heart failure for the chronic kidney disease patient

Influenza in dialysis patients: an opportunity to decrease mortality?

Molecular classification of membranous nephropathy.

Can incremental haemodialysis reduce early mortality rates in patients starting maintenance haemodialysis?

PPARγ and RhoBTB1 in hypertension.

Dilemmas and challenges in apolipoprotein L1 nephropathy research

Mechanisms of sodium retention in nephrotic syndrome.

Mitigating risk of aldosterone in diabetic kidney disease

Bisphosphonate therapy in CKD: the current state of affairs.

Interventions for improving outcomes in acute kidney injury.

Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease

New therapies for hyperkalemia

Occupational kidney stones.

Ten years in: APOL1 reaches beyond the kidney.

Fluid overload as a therapeutic target for the preservative management of chronic kidney disease.